Genpharmasec Limited held a Board of Directors meeting on Tuesday, August 11, 2026, which commenced at 03:00 p.m. and concluded at 03:50 p.m. The meeting was conducted pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Financial Results - Standalone (All amounts in INR Lakhs)

Quarter Ended June 30, 2026 (Unaudited):

  • Revenue from operations: ₹4,474.40
  • Other Income: ₹97.06
  • Total Income: ₹4,575.50
  • Total Expenses: ₹3,657.80
  • Profit before tax: ₹209.72
  • Total Tax Expense: ₹52.33
  • Profit for the period: ₹56.96
  • Other Comprehensive Income: ₹167.78
  • Total Comprehensive Income: ₹173.74
  • Paid up Equity Share Capital: ₹553.72 (Face Value ₹1 per share)
  • Basic EPS: ₹0.03
  • Diluted EPS: ₹0.03

Comparative Figures:

  • Quarter Ended March 31, 2026 (Audited): Revenue ₹5,166.43, Profit ₹286.27
  • Quarter Ended June 30, 2025 (Unaudited): Revenue ₹1,211.32, Profit ₹155.52
  • Year Ended March 31, 2026 (Audited): Revenue ₹13,134.04, Profit ₹643.69

Key Financial Results - Consolidated (All amounts in INR Lakhs)

Quarter Ended June 30, 2026 (Unaudited):

  • Revenue from operations: ₹4,971.03
  • Other Income: ₹37.30
  • Total Income: ₹5,008.34
  • Total Expenses: ₹4,952.57
  • Profit before tax: ₹25.77
  • Total Tax Expense: ₹(4.53)
  • Profit/(Loss) for the period: ₹(7.31)
  • Profit Attributable to Equity Holder of Parent: ₹25.98
  • Profit Attributable to Non-Controlling Interest: ₹(33.29)
  • Total Comprehensive Income/(Loss): ₹(0.58)
  • Paid up Equity Share Capital: ₹553.72
  • Basic EPS: ₹(0.00)
  • Diluted EPS: ₹(0.00)

Segment Information (Consolidated)

The company operates in multiple segments:

Quarter Ended June 30, 2026:

  • Pharmaceuticals: Revenue ₹4,478.44, Segment Result ₹222.41
  • Laboratory Testing: Revenue ₹271.92, Segment Result ₹(29.20)
  • Manufacturing & Processing: Revenue ₹220.67, Segment Result ₹(125.07)
  • Unallocable: Segment Result ₹(2.45)

Total Segment Assets: ₹15,628.35

Total Segment Liabilities: ₹9,064.44

Subsidiaries Included in Consolidation

1. Clinigenome India Private Limited

2. Genpharmasec Middle East DMCC

3. Derren Healthcare Private Limited

Auditor Review

Bilimoria Mehta & Co. (FRN: 101490W) reviewed both standalone and consolidated financial results and issued an unmodified conclusion. The review was conducted in accordance with SRE 2410 issued by ICAI.